Medical Cannabis Research

Marijuana Use In Hepatitis C Infection

Marijuana Use In Hepatitis C Infection
From 2014 research published in the Canadian Journal of Gastroenterology on the use of cannabis while being treated for Hepatitis C comes this study that concludes: “Our analysis did not identify clear benefit or harm attributable to marijuana use on measures of liver histology.”

 

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality

Medical Cannabis Laws and Opioid Analgesic Overdose Mortality
As reported in the August, 2014 issue of JAMA Internal Medicine, this research shares an examination of the association between medical cannabis laws and opioid analgesic overdose mortality. Each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time.

 

Stress-Induced Anxiety: Behavioral Reversal Through Endocannabinoid Augmentation

Stress Induced Anxiety and Cannabis | Cannabis for Anxiety
Published in the July 2014 issue of Translational Psychiatry, this study out of Vanderbilt University provides support that endocannabinoid augmentation is a viable pharmacological strategy for the treatment of stress-related neuropsychiatric disorders.

 

Clinical Endocannabinoid Deficiency (CECD)

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
This 2004 study by Ethan Russo, published in the journal Neuroendocrinology, examines the concept of clinical endocannabinoid deficiency and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis.  

Medical Cannabis Strain Content Satisfaction

Medical Cannabis Strain Content Satisfaction
This study, published in the June 2014 issue of the Journal of Clinical Psychopharmacology, describes more than 100 patients reporting about the therapeutic satisfaction with their pharmaceutical-grade cannabis product. Furthermore, differences in subjective effects among the available strains are investigated.

 

Intratumor THC For Glioblastoma Multiforme

Intratumor THC For Glioblastoma Multiforme
Published in the British Journal of Cancer in 2006, these scientists reported ‘the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. The patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression’.

 

Out Of The Shadows

Out Of The Shadows
Published in the Spring 2014 issue of Sonoma Medicine, this article asks physicians to: “For just a few minutes, try to set aside your ideas and opinions about cannabis. Forget about the pot-heads, the pot-docs, the stoners, the jokes, the dispensaries, the bud tenders and the feds.”